Trial Profile
To study immune-mediated adverse events and corticosteroid use after treatment with pembrolizumab in patients with non small cell lung cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Oct 2015 New trial record